Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Non-Current Assets: 2020-2024

Historic Non-Current Assets for Autolus Therapeutics (AUTL) over the last 5 years, with Dec 2024 value amounting to $121.8 million.

  • Autolus Therapeutics' Non-Current Assets rose 34.74% to $147.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $147.4 million, marking a year-over-year increase of 34.74%. This contributed to the annual value of $121.8 million for FY2024, which is 21.70% up from last year.
  • According to the latest figures from FY2024, Autolus Therapeutics' Non-Current Assets is $121.8 million, which was up 21.70% from $100.1 million recorded in FY2023.
  • Autolus Therapeutics' Non-Current Assets' 5-year high stood at $121.8 million during FY2024, with a 5-year trough of $3.0 million in FY2020.
  • Over the past 3 years, Autolus Therapeutics' median Non-Current Assets value was $100.1 million (recorded in 2023), while the average stood at $95.5 million.
  • Per our database at Business Quant, Autolus Therapeutics' Non-Current Assets surged by 2,085.85% in 2021 and then declined by 2.71% in 2022.
  • Yearly analysis of 5 years shows Autolus Therapeutics' Non-Current Assets stood at $3.0 million in 2020, then spiked by 2,085.85% to $66.3 million in 2021, then declined by 2.71% to $64.5 million in 2022, then soared by 55.15% to $100.1 million in 2023, then increased by 21.70% to $121.8 million in 2024.